TVARDI THERAPEUTICS INC (TVRD) Fundamental Analysis & Valuation

NASDAQ:TVRD • US1407553072

3.92 USD
+0.25 (+6.67%)
At close: Mar 13, 2026
3.92 USD
0 (0%)
After Hours: 3/13/2026, 8:01:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TVRD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

TVRD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While TVRD seems to be doing ok healthwise, there are quite some concerns on its profitability. TVRD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. TVRD Profitability Analysis

1.1 Basic Checks

  • In the past year TVRD has reported negative net income.
  • In the past year TVRD has reported a negative cash flow from operations.
  • TVRD had negative earnings in 4 of the past 5 years.
  • In the past 5 years TVRD always reported negative operating cash flow.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • TVRD has a Return On Assets of -35.74%. This is comparable to the rest of the industry: TVRD outperforms 45.08% of its industry peers.
  • The Return On Equity of TVRD (-50.04%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -35.74%
ROE -50.04%
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • TVRD's Gross Margin of 161.95% is amongst the best of the industry. TVRD outperforms 99.48% of its industry peers.
  • TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 161.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TVRD Health Analysis

2.1 Basic Checks

  • TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TVRD has more shares outstanding than it did 1 year ago.
  • TVRD has more shares outstanding than it did 5 years ago.
  • TVRD has a worse debt/assets ratio than last year.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -2.82, we must say that TVRD is in the distress zone and has some risk of bankruptcy.
  • TVRD has a Altman-Z score of -2.82. This is comparable to the rest of the industry: TVRD outperforms 42.49% of its industry peers.
  • There is no outstanding debt for TVRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.82
ROIC/WACCN/A
WACC8.75%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • TVRD has a Current Ratio of 3.48. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.48, TVRD perfoms like the industry average, outperforming 56.48% of the companies in the same industry.
  • A Quick Ratio of 3.48 indicates that TVRD has no problem at all paying its short term obligations.
  • TVRD's Quick ratio of 3.48 is in line compared to the rest of the industry. TVRD outperforms 57.51% of its industry peers.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. TVRD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 85.68% over the past year.
  • Looking at the last year, TVRD shows a very negative growth in Revenue. The Revenue has decreased by -34.36% in the last year.
  • TVRD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.54% yearly.
EPS 1Y (TTM)85.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.87%
Revenue 1Y (TTM)-34.36%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to decrease by -9.61% on average over the next years.
  • The Revenue is expected to grow by 0.01% on average over the next years.
EPS Next Y-91.17%
EPS Next 2Y-26.57%
EPS Next 3Y-40.39%
EPS Next 5Y-9.61%
Revenue Next Year-93.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y0.01%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. TVRD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TVRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • A cheap valuation may be justified as TVRD's earnings are expected to decrease with -40.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.57%
EPS Next 3Y-40.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TVRD Dividend Analysis

5.1 Amount

  • TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TVRD Fundamentals: All Metrics, Ratios and Statistics

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (3/13/2026, 8:01:21 PM)

After market: 3.92 0 (0%)

3.92

+0.25 (+6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09
Earnings (Next)05-11
Inst Owners30.16%
Inst Owner Change5.63%
Ins Owners15.36%
Ins Owner Change0%
Market Cap36.77M
Revenue(TTM)4.02M
Net Income(TTM)-13.95M
Analysts78.57
Price Target15.15 (286.48%)
Short Float %12.45%
Short Ratio8.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.65%
Min EPS beat(2)-71.45%
Max EPS beat(2)42.14%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.14
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-8.36
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0.43
BVpS2.97
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.74%
ROE -50.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 161.95%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z -2.82
F-Score2
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.87%
EPS Next Y-91.17%
EPS Next 2Y-26.57%
EPS Next 3Y-40.39%
EPS Next 5Y-9.61%
Revenue 1Y (TTM)-34.36%
Revenue growth 3Y-32.3%
Revenue growth 5Y-18.54%
Sales Q2Q%-100%
Revenue Next Year-93.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y0.01%
EBIT growth 1Y69.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y12.96%
EBIT Next 5YN/A
FCF growth 1Y77.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.75%
OCF growth 3YN/A
OCF growth 5YN/A

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the fundamental rating for TVRD stock?

ChartMill assigns a fundamental rating of 2 / 10 to TVRD.


What is the valuation status of TVARDI THERAPEUTICS INC (TVRD) stock?

ChartMill assigns a valuation rating of 0 / 10 to TVARDI THERAPEUTICS INC (TVRD). This can be considered as Overvalued.


What is the profitability of TVRD stock?

TVARDI THERAPEUTICS INC (TVRD) has a profitability rating of 1 / 10.


What is the expected EPS growth for TVARDI THERAPEUTICS INC (TVRD) stock?

The Earnings per Share (EPS) of TVARDI THERAPEUTICS INC (TVRD) is expected to decline by -91.17% in the next year.